TTrialPathMatch Me to Trials
← Back to trials
RecruitingColorectal AdenocarcinomaStage I Colorectal Cancer AJCC v8Stage II Colorectal Cancer AJCC v8

Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study

Eligible age

18+ yrs

Accepts

All genders

Locations

6 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This study investigates if circulating tumor DNA (ctDNA) and other tumor-related molecules/chemicals released in the blood can help doctors predict if colorectal cancer may come back or spread. Tumors shed DNA and other cancer related chemicals into the blood that can be identified and studied further to provide information about the cancer. Information gathered from this study may help researchers better understand if ctDNA found in the blood can predict whether colorectal cancer may come back or spread.

Sponsor: M.D. Anderson Cancer Center

You may qualify if…

  • 1. Age ≥ 18 years.
  • 2. Histological/cytological confirmation of colorectal adenocarcinoma.
  • 3. Patients with any stage colorectal adenocarcinoma deemed potentially eligible for curative intent treatment. Patients with stages II-IV colorectal cancer post-R0 resection may also be enrolled onto the protocol any time before or up to 3 months post-surgery and prior to initiating adjuvant therapy.
  • 4. Ability to understand and the willingness to sign a written informed consent document.
  • 5. Willing to pursue standard of care surveillance post completion of curative therapies.
  • 6. Willing to provide blood samples for correlative research.

You may not qualify if…

  • 1. Known active malignancies other than colorectal adenocarcinoma that may interfere with detection and / or interpretation of circulating plasma markers. Patients with known clonal hematopoiesis of indeterminate potential are eligible.
  • 2. Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.

Where it's recruiting

Arizona

Gilbert

Florida

Jacksonville

Hawaii

Honolulu

Idaho

Boise

Texas

Dallas · Houston · San Antonio · Temple

Source: ClinicalTrials.gov · NCT04739072 · last updated 2026-05-29